Rexulti patent?

When does the Rexulti patent expire?

Rexulti (brexpiprazole) is an antipsychotic medication developed by Otsuka Pharmaceutical. The drug was approved by the US FDA in 2015 for the treatment of schizophrenia and as an adjunct to antidepressant therapy in adults with major depressive disorder.

According to DrugPatentWatch.com [1], the Rexulti patent is owned by Otsuka Pharmaceutical and Lundbeck A/S, a Danish pharmaceutical company. The patent for brexpiprazole is set to expire in 2028 in the United States.

What is the current patent status of Rexulti?

The Rexulti patent was granted to Otsuka Pharmaceutical in 2012 [2]. The patent covers the use of brexpiprazole for the treatment of schizophrenia and as an adjunct to antidepressant therapy in adults with major depressive disorder.

Are there any biosimilars or generic alternatives to Rexulti?

As the patent for Rexulti is set to expire in 2028, it is likely that biosimilars or generic alternatives will enter the market once the patent expires. However, as of now, no biosimilars have been approved by the US FDA for brexpiprazole.

What is the global market landscape for Rexulti?

Rexulti is marketed by Otsuka Pharmaceutical in collaboration with Lundbeck A/S. The drug is sold in over 70 countries worldwide, including the United States, Canada, and several countries in Europe and Asia.

Sources:

[1] DrugPatentWatch.com. Brexpiprazole Patent Expiration Dates

[2] United States Patent and Trademark Office. Patent No. US 8,148,013 B2 (2012)

Additional Resources:

For more information on Rexulti, including clinical trial data and patient information, please visit the Otsuka Pharmaceutical website or consult a healthcare professional.

Note: This response is based on publicly available information and is subject to change as new data becomes available.